Carboplatin trials for Non-Small-Cell Lung Cancer

All Carboplatin trials · All Non-Small-Cell Lung Cancer trials

Phase breakdown

Recruiting trials studying Carboplatin for Non-Small-Cell Lung Cancer

• A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
  NCT07190248 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 205 locations
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
  NCT06692738 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 325 locations
• A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer
  NCT05654454 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 28 locations
• A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)
  NCT06822543 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
  NCT06793215 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 268 locations
• A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
  NCT05789082 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 71 locations
• A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer
  NCT07623356 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)
  NCT07642024 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
  NCT05104788 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
  NCT06561685 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 33 locations
• A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
  NCT06731907 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 41 locations
• A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
  NCT07229729 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
  NCT07622186 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 27 locations
• A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
  NCT06312137 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 269 locations
• A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
  NCT06561386 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 322 locations
• AB122 Platform Study
  NCT04999761 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer
  NCT05377658 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
  NCT04332367 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
  NCT05142189 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 45 locations
• DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC
  NCT06364917 · Phase: Phase 2 · Ages: 18 Years to 89 Years · Sex: All (male and female) · 1 location
• DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
  NCT07070440 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
  NCT05800587 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer
  NCT05766800 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
  NCT05800340 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)
  NCT07153445 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
  NCT05061550 · Phase: Phase 2 · Ages: 18 Years to 95 Years · Sex: All (male and female) · 97 locations
• Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
  NCT04585490 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
  NCT06745882 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
  NCT05579366 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 66 locations
• SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.
  NCT05351788 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
  NCT06047379 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
  NCT06712316 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 262 locations
• Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
  NCT07100080 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 186 locations
• Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
  NCT05098132 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 47 locations
• Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  NCT06236438 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 61 locations
• Using ctDNA to Determine Therapies for Lung Cancer
  NCT04966663 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many trials study Carboplatin for Non-Small-Cell Lung Cancer?

36 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.